IMA-901 / Immatics - LARVOL DELTA

Phase I/II study of multipeptide cancer vaccine IMA901 in Japanese patients with advanced renal cell cancer with long-term follow up (EAU 2023) - No abstract available

Clinical • Metastases • P1/2 data • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Editorial Comment to Phase I/II study of multipeptide cancer vaccine IMA901 after single-dose cyclophosphamide in Japanese patients with advanced renal cell cancer with long-term follow up. (PubMed, Int J Urol) - No abstract available

Journal • P1/2 data • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Phase I/II study of multipeptide cancer vaccine IMA901 after single-dose cyclophosphamide in Japanese patients with advanced renal cell cancer with long-term follow up. (PubMed, Int J Urol) - "This study demonstrated the safety and tolerability of IMA901 vaccine in Japanese RCC patients, and also showed that vaccination elicited an immune response."

Journal • P1/2 data • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • CSF2

De-risking clinical trial failure through mechanistic simulation. (PubMed, Immunother Adv) - "This is illustrated with a T-cell activation model, used to simulate the clinical trials of IMA901, a short-peptide cancer vaccine...These insights were used to hypothesise alternate trial designs predicted to improve efficacy outcomes. This framework illustrates how mechanistic models can complement clinical, experimental, and data-driven studies to understand, test, and improve trial designs, and how results may differ between humans and mice."

Journal • Oncology

Single-dose cyclophosphamide synergizes with immune responses to the renal cell cancer vaccine IMA901 (Oncoimmunology) - P=NA, N=NA; PMID: 23482454; "... findings demonstrate that the breadth of immune responses was associated with clinical benefits and that single-dose cyclophosphamide reduced the amount of regulatory T cells and was associated with prolonged survival after vaccination."

Biomarker • Renal Cell Carcinoma

Immatics' renal cancer vaccine IMA901 completes phase 3 patient recruitment and is granted US orphan drug designation by the FDA (Biz Journal) - P3, N=345, IMPRINT; Trial completed patient inclusion and around 345 patients will be randomized across 10 countries in the US and Europe, and also IMA901 has been granted orphan drug designation from (FDA) for the treatment of renal cell carcinoma in HLA-A*02 positive patients

Enrollment closed • Orphan drug • Oncology • Renal Cell Carcinoma

"@IMA1901 #Member Companies Among 'World's #Most #Ethical' https://t.co/DFQ6sRGk83 @AnthemInc @LillyPad @NiSourceInc @OldNationalBank" (@IMA1901)

Biosimilar

Immunotherapy of renal cell cancer (PubMed, Magy Onkol) - "The newest checkpoint agents, vaccination and pegylated interleukin-2 are also presented. The most promising clinical trials (CheckMate-025, AGS-003, IMA 901) and the on-going first line phase III trials are shown in metastatic clear cell renal carcinoma."

Journal

"@IMA1901 @WellnessIndiana @INSheriffAssn @PhRMA @TrustedMentors" (@RALIIndiana)

"The @IIB Guest List! @AnnMurtlow @uwci Jon Mills @Cummins @DonAquilano @AllosVentures @MattGreller @AimIndiana @ScottFadness @brittsmithindy Mark Dresen @LillyPad Stephanie Wells @IMA1901 Roger VanDerSnick @Colts Jim Schellinger @IndysOriginalJO @DrAllisonBarber @DrMattWill" (@GerryDick)